EXEL: the cashflow

MyFinsight

For the quarter ending 2025-10-03.

Cash Flow Overview

No enough data to generate the overview

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Cash Flow	2025-10-03	2025-07-04	2025-04-04	2024-09-27
Revenues	1,721,463	-	-	-
Cost of goods sold	57,216	-	-	-
Drug discovery	63,448	-	-	-
Development	421,021	-	-	-
Selling, general, and administrative	336,835	-	-	-
Other segment items	206,212	-	-	-
Interest income	51,787	-	-	-
Provision for income taxes	150,476	-	-	-
Net income	538,042	344,464	159,616	381,406
Depreciation and amortization	22,109	14,687	7,345	21,161
Impairment of long-lived assets	0	-	-	64,238
Stock-based compensation	92,886	62,001	25,930	67,490
Non-cash lease expense	18,210	12,166	6,096	21,111
Acquired in-process research and development technology	6,999	750	0	31,250
Other, net	9,261	10,617	4,786	9,247
Trade receivables, net	44,207	26,837	16,119	32,192
Inventory	1,581	-2,568	71	-2,691
Prepaid expenses and other assets	36,737	84,386	-20,320	63,068
Accrued collaboration liabilities	1,544	641	4,605	-1,003
Accounts payable and other liabilities	-37,252	-55,007	8,501	-24,129
Net cash provided by operating activities	550,752	260,430	211,437	459,708
Purchases of marketable securities	477,556	288,186	186,701	622,522
Proceeds from maturities and sales of marketable securities	833,527	612,021	258,917	651,148
Purchases of property, equipment and other, net	7,272	5,790	2,952	24,458
Acquired in-process research and development technology	25,499	20,250	19,500	27,750
Net cash provided by (used in) investing activities	323,200	297,795	49,764	-23,582
Payments for repurchases of common stock	689,893	585,858	283,934	461,621
Proceeds from issuance of common stock under the equity incentive plan and stock purchase plan	41,262	37,710	11,627	43,027
Taxes paid related to net share settlement of equity awards	66,395	63,018	22,516	22,180
Net cash used in financing activities	-715,026	-611,166	-294,823	-440,774
Net increase (decrease) in cash and cash equivalents	158,926	-52,941	-33,622	-4,648
Cash and cash equivalents at beginning of period	217,374	-	-	-
Cash and cash equivalents at end of period	376,300	-	-	-

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Time Plot

Show the time plot by selecting a row from the table.

EXEL: the cashflow